FBIO News and Press, Fortress Biotech Inc. From 03/11/24

BAER-101 demonstrated full suppression of seizure activity in SynapCell's GAERS model of absence epilepsy, a proven indicator of efficacy in anti-seizure drug development with high predictability of response in humans MIAMI, March 11, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Na...

MB-101 was well-tolerated and 50% of patients achieved stable disease or better with two partial responses and two complete responses lasting 7.5 and 66+ months, respectively ~70% improvement in median overall survival compared to expected survival rate in cohort with dual intratumoral (I...

Encouraging preclinical studies demonstrate potential to combine AAV-ATP7A gene therapy with CUTX-101, which could be the first FDA-approved treatment for Menkes disease Cyprium Therapeutics, a majority-owned subsidiary of Fortress Biotech, is developing AAV-ATP7A gene therapy to be use...

--News Direct-- New York, Feb 2, 2024 - ( Plato Data via 500NewsWire) -- Fortress Biotech (Fortress Bio), a unique biotech company led by industry veteran Dr. Lindsay Rosenwald , focused on identifying, in-licensing and developing high-potential marketed drugs ...

WALTHAM, Mass., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that it has entered into a definitive agreement with a single healthcare-dedicated institution...

WORCESTER, Mass., Jan. 11, 2024 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for...

WALTHAM, Mass., Jan. 11, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that James Oliviero, President and Chief Executive Officer, will participate in a fireside cha...

MIAMI, Jan. 11, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced tha...

2024-01-09 08:35:20 ET BT Brands  ( BTBD ) +135% . Sentage Holdings ( SNTG ) +95% . Juniper Networks  ( JNPR ) +23% jumps 25% on report HPE is nearing buyout deal. Syra Health  ( SYRA ) +17% . Elicio Therapeutics  ( ELT...

2024-01-05 09:20:37 ET More on Journey Medical, Dr. Reddy's, etc. The Strategic Evolution Of Journey Medical In Dermatological Care Dr. Reddy's Laboratories: Q2 Earnings Reveals Strong Growth And Promising Advancements Journey Medical Corporation (DERM) Q3 2023 Earni...